b-lymphocyte stimulator
Recombinant proteinexperimental
B-cell activating factor (BAFF) also known as tumor necrosis factor ligand superfamily member 13B and CD257 among other names, is a protein that in humans is encoded by the TNFSF13B gene. BAFF is also known as B Lymphocyte Stimulator (BLyS) and TNF- and APOL-related leukocyte expressed ligand (TALL-1) and the Dendritic cell-derived TNF-like molecule. — Wikipedia
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2001 (NCT00024934)
Timeline
2000s
- Jan 1, 2001
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Tumor necrosis factor ligand superfamily member 13BSupplementation
TNFSF13B supplementation
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaB-cell activating factor ↗
Also known as
- b-lymphocyte stimulator
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00024934 | Phase 1 | Oct 1, 2001 | National Cancer Institute (NCI) |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 2001 |
1 organizations
Page 1 / 1